Inivata Information, Including Revenue, Investors, Funding, Competitors & Key Metrics

Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.

Repeat Founder
Company Highlights
Year Founded

2014

icon-altStatus

Acquired

icon-altEmployees

46

Location (HQ)

USA

Since Last Funding

3 years 9 months

Monthly Website Visitors

42.4K

icon-altTotal Investment Amt

$200M

Last Funding Round

Series C

icon-altYoY Headcount Growth

-16.33%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Biotechnology

Health Care

Biotechnology Research

Medical Device

Genetics